Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

TRAX stock hub

First Tracks Biotherapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TRAXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

679M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

TRAX

In the news

Latest news · TRAX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-48.9

P25 -105.6P50 -46.5P75 -3.1

ROIC-31.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TRAX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

128

Groups with data

Currency

USD

Showing 128 of 128 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Company name	First Tracks Biotherapeutics, Inc.
Country	United States
Country code	US
Employees	104
Enterprise value	$381.5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US3371851029
Last refreshed	2026-05-10
Market cap	$679M
Market cap category	Small-Cap
Price	$19.54
Price currency	USD
Sector	Healthcare
Symbol	TRAX

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-24.46%
FCF yield	-21.06%
P/B ratio	2.36x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-139.6M
Net Income	$-166.1M
Net Income Growth Years	0%
Profit Per Employee	$-1.6M
ROA	-28.97
ROCE	-59.76
ROE	-48.91
ROIC	-31.55

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$330.5M
Cash	$311.6M
Current Assets	$316.4M
Current Liabilities	$31M
Debt	$14.1M
Debt Equity	$0.05
Equity	$287.5M
Liabilities	$43.1M
Long Term Assets	$14.1M
Long Term Liabilities	$12M
Net Cash	$297.5M
Net Cash By Market Cap	$43.82
Net Debt Equity	$-1.03
Tangible Book Value	$287.5M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.2
Net Working Capital	$-24.2M
Quick ratio	10.05
Working Capital	$285.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
All Time High	26.8
All Time High Change	-27.09%
All Time High Date	2026-04-17
All Time Low	14.79
All Time Low Change	32.12%
All Time Low Date	2026-04-20
ATR	2.9
Beta1y	-0.82
High	19.82
High52	26.8
High52 Date	2026-04-17
High52ch	-27.09%
Low	17.5
Low52	14.79
Low52 Date	2026-04-20
Low52ch	32.12%
RSI	49.28
RSI Monthly	0
RSI Weekly	0
Sharpe ratio	0.92x
Sortino ratio	1.58
Tr1m	2.84%
Tr1w	-12.69%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	3
Analyst Price Target Top	$39
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Operating Income	$-179M
Price target	$41
Price Target Change	$110
Price Target Change Top	$99.59

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	30,939,031%
Float Percent	89.04%
Shares Insiders	1.83%
Shares Institutions	4.38%
Shares Out	34,748,841

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-175.3M
Average Volume	464,469.4x
CAPEX	$-87,000
Ch1m	2.84
Ch1w	-12.69
Change	9.65%
Change From Open	7.84
Close	17.82
Days Gap	1.68
Depreciation Amortization	559,000
Dollar Volume	6,938,829.9
Earnings Date	2026-06-01
EBIT	$-179M
EBITDA	$-178.4M
F Score	1
FCF	$-143M
FCF EV Yield	-37.49x
FCF Per Share	$-4.12
Financing CF	30,010,000
Fiscal Year End	December
Founded	2,025
Investing CF	228,032,000
Is Primary Listing	1
Is Spac	No
Last Split Type	Never
Ma20	20.91
Ma20ch	-6.54%
Net CF	115,116,000
Next Earnings Date	2026-06-01
Open	18.12
Optionable	No
Position In Range	87.93
Post Close	19.54
Postmarket Change Percent	-7.27
Postmarket Price	$18.12
Ppne	13,889,000
Price Date	2026-05-08
Ptbv Ratio	2.36
Relative Volume	0.76x
Share Based Comp	32,300,000
Us State	California
Volume	355,109

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does TRAX pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns TRAX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+4.4%

Float: +89.0% of shares outstanding

Insider ownership

+1.8%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

n/a

Negative means the company is buying back shares.

Technical

TRAX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

49.3

Neutral momentum band

Price vs 200-day MA

n/a

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.92

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TRAX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TRAX stock rating?

First Tracks Biotherapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TRAX analysis?

The full report lives at /stocks/TRAX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TRAX?

The latest report frames TRAX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TRAX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.